US20220047506A1

US20220047506A1 - Praziquantel Formulations

Info

Publication number: US20220047506A1
Application number: US16/991,397
Authority: US
Inventors: William Miller
Original assignee: Villya LLC
Current assignee: Villya LLC
Priority date: 2020-08-12
Filing date: 2020-08-12
Publication date: 2022-02-17
Also published as: EP4196225A1; CN116056704A; US12390417B2; EP4196225A4; US20220142920A1; WO2022035674A1

Abstract

Praziquantel may be formulated to enhance its pharmacokinetic, toxicity, and palatability properties. It can be stored and/or dispensed as a liquid, powder, or tablet. Reduction in the most common side effects improves patient compliance and satisfaction. Altered taste profile improves patient compliance and satisfaction. Once formulated it can be used to treat a variety of blood flukes and worms in human and veterinary subjects.

Description

TECHNICAL FIELD OF THE INVENTION

This invention is related to the area of formulations and treatments for parasite infections. In particular, it relates to praziquantel formulations.

BACKGROUND OF THE INVENTION

Praziquantel is a medication used to treat a number of types of parasitic worm infections. Specifically it is used for schistosomiasis, clonorchiasis, opisthorchiasis, tapeworm infections, cysticercosis, hydatid disease, and other fluke infections. Often the treatment with Praziquantel leads to unwanted side effects, such as gastrointestinal discomfort attributed to build up of immobilized or killed parasites. Reported side effects include: headache, dizziness, stomach pain, nausea, tiredness, weakness, joint/muscle pain, loss of appetite, vomiting, and sweating. These side effects can harm the patient and makes the experience of using the drug unpleasant and may discourage patient compliance with prescribed medicine.
Praziquantel ((RS)-2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one) (C₁₉H₂₄N₂O₂) is represented as:
There is a continuing need in the art to treat parasites with reduced side effects.

SUMMARY OF THE INVENTION

According to one embodiment of the invention a liquid pharmaceutical formulation is provided. The formulation comprises: polyethylene glycol (PEG); rubusoside; and praziquantel.
Another embodiment is a method of treating an infection by a blood fluke or tapeworm in a patient. A liquid pharmaceutical formulation is administered to the patient. The formulation comprises: polyethylene glycol (PEG); rubusoside; and praziquantel.
Yet another embodiment is a powdered formulation of praziquantel for reconstitution in water and subsequent administration to a patient as a liquid formulation. The powdered formulation comprises: polyethylene glycol (PEG); rubusoside; and praziquantel.
In still another embodiment a powdered formulation of praziquantel is provided. The powdered formulation comprises: rubusoside; and praziquantel.
These and other embodiments which will be apparent to those of skill in the art upon reading the specification provide the art with improvements in patient compliance, satisfaction, comfort, and overall treatment experience.

DETAILED DESCRIPTION OF THE INVENTION

The inventor has developed a method of formulating praziquantel so that it is easily, accurately, and pleasantly administered and reduces one or more side effects associated with its use. Additional benefits to pharmacokinetic properties may also accrue.
The current practice in the art is to dispense praziquantel as a large tablet that must be split—sometimes into multiple segment—to achieve a proper dose for a patient. By using a powdered or liquid formulation, dispensing proper doses is easier, reducing errors, variations, and waste based on variations in pill splitting technique.
Praziquantel is only moderately soluble in water. According the Merck Index, its solubility is 400 mg/l. However, the combination of elements in the formulations as disclosed here are able to achieve a higher degree of solubility, permitting liquid dosing in a palatable volume. The liquid or powdered formulation comprises: polyethylene glycol (PEG); rubusoside; and praziquantel. The pharmacokinetic properties such as absorption may also be altered by this combination.
The ratio of rubusoside to praziquantel in the formulation may range from about 2:1 to about 10:1. This may be adjusted to achieve a suitable solubility level, gastrointestinal absorption, and agreeable taste profile.
In some cases the combination may be used to form a liquid formulation. In other instances it may be desirable to use it to form a tablet.
Polyethylene glycol as used in the liquid and powdered formulations has an average molecular weight large enough for the polymer to serve as an osmotic laxative. Typically this is between 2000 and 6000 daltons, between 3000 and 4500, or between 3200 and 3700. Popular commercially available versions are 3350, 4000 and 6000. The preparation of PEG may be polydisperse or monodisperse, for example. If polydisperse, then the molecular weight describes the weighted average molecular weight of the preparation. According to the formulations in powder or liquid form, the ratio of PEG to praziquantel may range between and including 5:1 and 10:1. In one embodiment the ratio is about 8:1.
For administration, the powdered form may be reconstituted in a liquid vehicle, either at the point of manufacture, at the dispensing pharmacy, or by the patient. The liquid vehicle may be water, a buffered aqueous solution, or an aqueous beverage, such as an energy drink or electrolyte rich drink. Alternatively, the powdered preparation of rubusoside and praziquantel may be constituted in a tablet or pill—with or without PEG. Suitable ingredients for a tablet or pill may include any or all of corn starch, magnesium stearate, microcrystalline cellulose, povidone, sodium lauryl sulfate, polyethylene glycol, titanium dioxide and hypromellose.
A variety of parasites and the diseases they cause may be treated using the formulations disclosed here. These include schistosomiasis (bilharzia, bilharziasis, or snail fever) caused by schistosomes, fluke infections caused by the trematode Clonorchis sinensis (Chinese or oriental liver fluke), trematodes Opisthorchis viverrini (Southeast Asian liver fluke) and Opisthorchis felineus (cat liver fluke), taeniasis or cysticercosis caused by the tapeworm species Taenia saginata (beef tapeworm), Taenia solium (pork tapeworm), and Taenia asiatica (Asian tapeworm), tiny tapeworms of the genus Echinocococcus causing either cystic echinococcosis (hydatid disease) or alveolar echinococcosis.
Patients which are treated can be either human or veterinary. Commonly infected veterinary animals include horse, dog, cat, poultry, cattle, pigs, and ruminants. Any of these can be treated using the formulations disclosed here.
The above disclosure generally describes the present invention. All references disclosed herein are expressly incorporated by reference. A more complete understanding can be obtained by reference to the following specific examples which are provided herein for purposes of illustration only, and are not intended to limit the scope of the invention.

Example 1

Compounding of Praziquantel with Rubusoside
Generally, ingredients are deposited into a sealed container with ethanol and vortex-mixed to form a solution. The solution is subjected to centrifugation. The ethanol is evaporated off and dried mixture is dissolved in water. This mixture is centrifuged again and the supernatant is filtered though a membrane. The flow-through is dried the forming the compounded praziquantel.
In a specific example of making the liquid praziquantel, it is mixed with Rubusoside to create a water soluble chemical. The formulation ratio (10/1) being 100 mg of Rubusoside to 10 mg praziquantel is prepared. Ingredients are deposited into a sealed container with 1 ml of ethanol and vortex for 15 minutes to form a solution. Then the mixture is subjected to centrifugation at 12,000 rpm for 10 min. Next, the ethanol is evaporated off and mixture is then dissolved in 1 ml of water. This mixture is centrifuged again at 12,000 rpm for 10 minutes and filtered though a 0.20 μm membrane and dried. The resulting mixture can be used to make a liquid formulation of praziquantel when reconstituted in water. This gives 110 mg solids in the formula at a 10/1 ratio.
To adjust sweetness and solubility this formula can vary from 2/1 ratio-10/1 ratio depending on conditions.

Example 2

Formulating the Compounded Praziquantel/Rubusoside in a Liquid


Praziquantel (liquid recipe 10/1)	7,333.37	mg
Glycol 3350	5,666.67	mg
Croscarmellose sodium	43.17	mg
Providone	43.17	mg
Sodium Laurel Sulfate	43.17	mg
Magnesium Stearate	43.17	mg
Brilliant Blue FCF (Blue1)	43.17
Total	13,216.22	mg

Inactive ingredients and active ingredients (praziquantel liquid recipe 10/1 and Glycol 3350; see Example 1) are mixed to homogeneity. The mixture is then reconstituted with 2.667 oz of purified water and a flavor enhancer such as FLAVORx. The dose for an adult human is 20 mg of praziquantel per kg 3× daily, e.g., every 5 hours during wakeful hours.

Claims

1. A liquid pharmaceutical formulation in a vehicle consisting of an aqueous vehicle, said formulation comprising:

(a) polyethylene glycol (PEG);

(b) rubusoside; and

(c) praziquantel.

2. The liquid pharmaceutical formulation of claim 1 wherein the PEG is polydisperse.

3. The liquid pharmaceutical formulation of claim 1 wherein the PEG has an average molecular weight of 2000-6000.

4. The liquid pharmaceutical formulation of claim 1 wherein the PEG is PEG 3350.

5. The liquid pharmaceutical formulation of claim 1 wherein the weight ratio of PEG to praziquantel is between 5:1 and 10:1.

6. The liquid pharmaceutical formulation of claim 1 wherein the weight ratio of rubusoside to praziquantel in the liquid pharmaceutical formulation is between 2:1 and 10:1.

7. A method of treating an infection by a blood fluke or tapeworm in a patient, comprising:

administering the liquid pharmaceutical formulation of claim 1 to the patient.

8. The method of claim 7 wherein the patient is a human.

9. The method of claim 7 wherein the patient is a veterinary patient.

10. The method of claim 7 wherein the infection is schistosomiasis.

11. The method of claim 7 wherein the blood fluke is Clonorchis sinensis.

12. The method of claim 7 wherein the blood fluke is Opisthorchis viverrini.

13. The method of claim 7 wherein the blood fluke is Opisthorchis felineus.

14. The method of claim 7 wherein the tapeworm is Taenia saginata.

15. The method of claim 7 wherein the tapeworm is Taenia solium.

16. The method of claim 7 wherein the tapeworm is Taenia asiatica.

17. The method of claim 7 wherein the infection is Echinococcosis.

18. The method of claim 7 wherein the patient is selected from the group consisting of a horse, dog, cat, poultry, and ruminant.

19. The method of claim 7 wherein the dose of praziquantel is between 10 and 40 mg per kg of patient weight.

20. The method of claim 7 wherein the patient is human and is administered 3 doses daily of between 10 and 40 mg per kg of patient weight.

21. The method of claim 7 wherein the dose of praziquantel is between 10 and 40 mg per kg of patient weight.

22. The method of claim 7 wherein the patient is human and is administered 3 doses daily of between 10 and 40 mg per kg of patient weight.

23. A powdered formulation of praziquantel and a vehicle consisting of an aqueous vehicle for reconstitution of said powdered formulation and subsequent administration to a patient as an aqueous liquid formulation, said powdered formulation comprising:

(a) polyethylene glycol (PEG);

(b) rubusoside; and

(c) praziquantel.

24. The powdered formulation of claim 23 wherein the PEG is polydisperse.

25. The powdered formulation of claim 23 wherein the PEG has an average molecular weight of 2000-6000.

26. The powdered formulation of claim 23 wherein the PEG is PEG 3350.

27. The powdered formulation of claim 23 wherein the weight ratio of PEG to praziquantel is between 5:1 and 10:1.

28. The powdered formulation of claim 23 wherein the weight ratio of rubusoside to praziquantel in the powdered formulation is between 2:1 and 10:1.

29. (canceled)

30. (canceled)

31. The liquid pharmaceutical formulation of claim 1 which consists of the aqueous vehicle and:

(a) polyethylene glycol (PEG);

(b) rubusoside; and

(c) praziquantel.

32. The powdered formulation and the vehicle of claim 23 wherein the powdered formulation consists of:

(a) polyethylene glycol (PEG);

(b) rubusoside; and

(c) praziquantel.

33. The liquid pharmaceutical formulation of claim 1 which contains one or more components selected from the group consisting of: buffered aqueous solution, an aqueous beverage, croscarmellose sodium, povidone, brilliant blue FCF, and a flavor enhancer.

34. The liquid pharmaceutical formulation of claim 1 which consists of the aqueous vehicle and

(a) polyethylene glycol (PEG);

(b) rubusoside; and

(c) praziquantel, and optionally one or more components selected from the group consisting of buffered aqueous solution, an aqueous beverage, croscarmellose sodium, povidone, brilliant blue FCF, and a flavor enhancer.

35. The powdered formulation and the vehicle of claim 23 wherein the powdered formulation consists of:

(a) polyethylene glycol (PEG);

(b) rubsoside; and

(c) praziquantel; and optionally one or more components selected from the group consisting of: croscarmellose sodium, povidone, brilliant blue FCF, and a flavor enhancer.

36. A method of formulating a powdered formulation of praziquantel for administration to a patient as an aqueous liquid formulation, said method comprising mixing a powdered formulation comprising:

(a) polyethylene glycol (PEG);

(b) rubusoside; and

(c) praziquantel;

with a vehicle consisting of an aqueous vehicle.